BioStock: Ultimovacs progresses on several fronts

The year’s third quarter saw Norwegian immuno-oncology developer Ultimovacs make several key advancements. Not only has the company progressed with its phase I clinical development of universal cancer vaccine UV1, but it has also announced the initiation of a fifth phase II trial with the candidate. To top things off, among other news, Ultimovacs was awarded dual Fast Track designation for UV1 from the FDA and raised 270 MNOK in a private placement.

Read the article at biostock.se:

https://www.biostock.se/en/2021/11/ultimovacs-progresses-on-several-fronts/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se